A meta-analysis of microRNAs with prognostic significance in pancreatic ductal adenocarcinoma

Frampton, Adam E.; Krell, Jonathan; Jamieson, Nigel B.; Gall, Tamara; Castellano, Leandro; Stebbing, Justin; Jiao, Long R.

doi:10.1016/j.pan.2014.05.664

Cited by 11 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Loss of function of tumor suppressor p53 occurs in 50-75% of PDACs (63). miR-34a is a direct transcriptional target of p53, whose expression is altered in pancreatic cancer (64,65). The epigenetic inactivation of miR-34a by CpG methylation is a common event during tumor progression (65).…”

Section: Angiomirs: Micrornas Modulating Angiogenesis In Human Cancersmentioning

confidence: 99%

AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

et al. 2018

View full text Add to dashboard Cite

Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored. Contents

show abstract

Section: Angiomirs: Micrornas Modulating Angiogenesis In Human Cancersmentioning

confidence: 99%

AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, a poor overall survival was found for high levels of miR-155 and miR-203 as well as low miR-34a levels. 122 In addition, among others, low-expression levels of miR-218 and miR-494 in tumor tissue as well as high miR-221/222 and miR-744 levels in tumor tissue and plasma, respectively, have been found to predict poor survival in PDAC patients. [123][124][125][126]…”

Section: Micrornasmentioning

confidence: 99%

Current and future biomarkers for pancreatic adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

Although pancreatic cancer is only the twelfth most common type of cancer in the world, it features a very unfavorable prognosis. The mortality rate almost equals the incidence rate, corroborating the very poor prognosis of pancreatic cancer. The 5-year survival rate for all stages of pancreatic ductal adenocarcinoma is only 7%. Surgical resection represents the only potentially curative treatment option for pancreatic ductal adenocarcinoma patients but is often not feasible due to the advanced stage of the disease upon diagnosis. For advanced disease, palliative chemotherapy is the treatment of choice although the regimens available to date are untargeted and have extensive side-effect profiles, making them unsuitable for patients with a low performance status. For this reason, early detection of pancreatic cancer is essential in order to provide patients with an optimal therapeutic approach. Up to the present day, carbohydrate antigen 19-9 is the only diagnostic marker approved by the U.S. Food and Drug Administration but its diagnostic potential is limited due to its restricted sensitivity and specificity, supporting the urgent need for novel biomarkers. In addition, prognostic and treatment-predictive biomarkers might provide essential information regarding personalized treatment decisions for individual patients. In this article, we aim to review current and future diagnostic, prognostic, and treatment-predictive biomarkers for pancreatic cancer.

show abstract

“…Prognostic role of some of these miRNAs (ie, miR-21, miR-155, miR-196a, miR-222 and miR-34a) has been deeply illustrated by Frampton et al 86 in a systematic review and meta-analysis focused on the impact of miRNAs on overall survival (OS) and disease-free survival in PDAC. In this study, the authors estimated the HR per each investigated miRNAs and concluded that miR-21 is a strong predictor of OS in resected PDAC (HR 2.72).…”

Section: Mirnas Deregulated In Solid Lesionsmentioning

confidence: 99%